

HOUSE COMMITTEE SUBSTITUTE

FOR

HOUSE BILL NO. 1169

AN ACT

To amend chapter 196, RSMo, by adding thereto one new section relating to required disclosures for certain products, with penalty provisions.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF MISSOURI, AS FOLLOWS:

Section A. Chapter 196, RSMo, is amended by adding thereto one new section, to be known as section 196.1400, to read as follows:

196.1400. 1. The following products sold, distributed for use, or administered to a person shall be clearly and conspicuously labeled so as to provide informed consent as described in subsection 2 of this section:

(1) Medicines or therapies designed with the intent to alter a person's genome;

(2) Gene therapies; and

(3) Messenger ribonucleic acid or other DNA or RNA products engineered or manufactured to have an effect in the human body.

2. The informed consent required for each product described in subsection 1 of this section shall include, but is not limited to:

(1) A clear and conspicuous label and explanation to any person affected by the product of the risks and benefits of the product, including any side effects and adverse events of special

interest; and

(2) A voluntary decision by a person to receive the product.

3. Farmers and ranchers not in the business of creating or engineering gene therapy products or products intended to or known to alter a person's genome more substantially than natural food are exempt from the provisions of this section.

4. Knowingly causing a person to receive into the person's body a medicine or therapy designed with the intent to alter a person's genome, a gene therapy, or messenger ribonucleic acid or any other DNA or RNA product engineered or manufactured to have an effect in the human body without the person's informed consent is a class A misdemeanor.